BD, a leading global medical technology company, announced U.S. Food and Drug Administration 510 clearance for the BD Respiratory Viral Panel for BD MAX™ System, a single molecular diagnostic combination test that identifies and distinguishes SARS-CoV-2, influenza A, influenza B, and Respiratory Syncytial Virus in approximately two hours.
